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Gerald D. Buckberg, MD
Until recently, myocyte stunning from inadequate cardiac protec-tion has been the main focus of interest and is most relevant indamaged hearts (ie, hypertrophy, unstable angina, and reducedejection fraction) in which vulnerability is accentuated. This in-jury is transient, since stunning recovers after brief inotropic ormechanical support. This editorial focuses on an expanding rec-
ognition that both the myocyte and the endothelium can be injured or stunned, as the
two limbs are interrelated.
Damaged hearts exhibit loss of endothelium-dependent factors and reduced nitric
oxide formation. The result is perioperative vasospasm, adherence of platelets, and
leukocyte attachment that also causes capillary obstruction with inhomogeneous
flow. The essential theme is that the endothelium is injured, because neutrophils do
not attach, then roll, and finally have parenchymal influence for oxygen radical
injury without such damage. This clinical report is the application of an experimen-
tally proven method to reduce the consequences of endothelial damage.
The transient nature of stunning is clear. Brief leukocyte depletion (ie, 95%
white blood cell reduction in this study) is quickly reversed by blood with a normal
white cell count. However, the persistence of functional benefits indicates that
residual protection is retained, including experimental markers of reduced endothe-
lial adherence of white cells.
The expertise of Dr Roth’s surgical team1 is apparent, with no intra-aortic balloon
counterpulsations or deaths in high-risk patients. Their carefully defined data
characterize the advantages of white blood cell reduction in patients with ejection
fractions of about 20%, through reduced needs for dopamine, absent enoxamine for
hemodynamic support, raised ejection fraction, diminished troponin release (a
myocardial marker of cellular injury), less ventricular fibrillation after aortic un-
clamping (presumably from improved excitation/contraction coupling), and, finally,
shorter intensive care unit stay (48 vs 60 hours), even though the last variant is not
significant due to increased vulnerability. These aforementioned “soft or surrogate”
end points conform precisely to their referenced reports of benefits of leukocyte
depletion in damaged hearts. Conversely, no benefit of leukocyte depletion has been
established in patients with an ejection fraction of more than 40%.
The merits of cardiac versus systemic leukocyte depletion are clear, since
systemic doses allowed only 38% reduction at the time of aortic unclamping. The
white cell filter becomes less functional after more than 1000 mL blood delivery, so
that selection of one versus two white blood filters becomes dependent on defining
the role of leukocyte depletion throughout all periods of cold blood cardioplegia
during aortic clamping, and/or only in the warm 500- to 700-mL reperfusate.
Surgical reperfusion strategies become confusing to our basic science and car-
diology colleagues, who address single events after short ischemic intervals,
whereas we confront prolonged ischemia for surgical repair. Unidimensional focus
on one element will not be successful because ischemia unmasks many changes. Our
study, quoted in the reference list,2 showed that white blood cell depletion alone
reduced reperfusion injury but failed to restore contractility unless leukocyte de-
pletion supplemented a more complex cardioplegic approach. The composite ap-
proach is clear from this study, since their blood cardioplegic solutions contain
potassium, glucose, citrate, and a buffer with good clinical results, even without
white blood cell depletion.1
We must establish cardiac surgical recognition of global endothelial stunning and
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develop efforts to reduce this injury during myocardial
protection. In damaged hearts, conventional cardioplegic
solutions can completely prevent myocyte injury, yet allow
endothelial damage with resultant white blood cell adher-
ence.3 A principal underlying mechanism is endothelial loss
of nitric oxide production, subsequently allowing the neu-
trophil and platelet adherence and changing vasoactivity to
impair subsequent vasodilatation. White blood cell adhesion
is only one step in this injury.
Our principal surgical dilemma relates both to dealing
with global stunning and understanding why this occurs.
The neutrophil filter addresses the lesions after they are
present, with acceptance that brief reperfusion interventions
can reduce endothelial injury. Studies that focus on main-
taining the intrinsic endothelium-dependent protective com-
ponent, nitric oxide generation, may be useful. Hiramatsu,4
Mizuno,3 Kronon,5 and their colleagues, discovered that
delivery of the natural nitric oxide precursor, L-arginine,
limits endothelial and myocyte damage, even without white
blood cell depletion. Consequently, leukocyte depletion
adds to the expanding catalog of strategies for surgical
correction, but efforts at preventing endothelial stunning,
rather than treating the injury, must be considered in the
future.
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